|
|
Volumn 364, Issue 5, 2011, Pages 393-395
|
|
Weighing the benefits and costs of HPV vaccination of young men
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
WART VIRUS VACCINE;
HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;
ANUS CANCER;
CANCER RISK;
CLINICAL ASSESSMENT;
CONDYLOMA ACUMINATUM;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG EFFICACY;
HEALTH CARE COST;
HUMAN;
HUMAN PAPILLOMAVIRUS TYPE 11;
HUMAN PAPILLOMAVIRUS TYPE 16;
HUMAN PAPILLOMAVIRUS TYPE 18;
HUMAN PAPILLOMAVIRUS TYPE 6;
PAPILLOMAVIRUS INFECTION;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
SHORT SURVEY;
UTERINE CERVIX CANCER;
VACCINATION;
ADOLESCENT;
ADULT;
DISEASE TRANSMISSION;
ECONOMICS;
FEMALE;
MALE;
NOTE;
SEXUALLY TRANSMITTED DISEASE;
UNITED STATES;
UTERINE CERVIX TUMOR;
ADOLESCENT;
ADULT;
COST-BENEFIT ANALYSIS;
DISEASE TRANSMISSION, INFECTIOUS;
FEMALE;
HUMANS;
MALE;
PAPILLOMAVIRUS INFECTIONS;
PAPILLOMAVIRUS VACCINES;
SEXUALLY TRANSMITTED DISEASES, VIRAL;
UNITED STATES;
UTERINE CERVICAL NEOPLASMS;
YOUNG ADULT;
|
|
EID: 79551524699
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1012246 Document Type: Short Survey |
|
Times cited : (30)
|
|
References (5)
|
